| Dr Tambuyzer, in your opinion, what are the main opportunities for US biotechnology companies operating in Europe? The first opportunity is that population-wise, Europe is the largest market for biopharmaceuticals in the world. One of the other important benefits is that Europe has a very high-quality research base providing the groundwork for a variety of innovative products and technologies. It is significant, however, that Europe has less drive and less experience than the US in converting this expertise into products and services for commercialisation. This provides strong business-oriented companies with the opportunity to forge many high-level research, clinical and/or technological collaborations in an environment that is less competitive than in the US. |
